Mico-Digest 2.0
Phase 3- Indications
- Colorectal cancer
Company intelligence / Profile preview
Hifas da Terra has over two decades of experience developing nutraceuticals based on medicinal mushrooms. The company reinvests a significant portion of profits into R&D (~62%), maintains one of Europe’s largest medicinal mushroom strain banks, and currently runs about fifteen clinical studies across multiple therapeutic areas. Its products are widely used by healthcare professionals internationally. The company was awarded the Nutraforum Best Nutraceutical Company award in Spain in September 2024 for its innovation and scientific rigor.[6]
1 more asset in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Hifas da Terra.